EMEA-001261-PIP01-11-M07
Key facts
| Invented name |
Halaven
|
| Active substance |
Eribulin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0535/2021
|
| PIP number |
EMEA-001261-PIP01-11-M07
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of soft tissue sarcoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Eisai Europe Ltd
Tel. +44 (0)20 8600 1400 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001261-PIP01-11-M07
|
| Compliance opinion date |
25/02/2022
|
| Compliance outcome |
positive
|